Verona Pharma PLC Holding(s) in Company (2914G)
May 25 2017 - 12:27PM
UK Regulatory
TIDMVRP
RNS Number : 2914G
Verona Pharma PLC
25 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Verona Pharma PLC
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
------------------------------------------------------------- --------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
-----------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
---------------------------------------------------------------- -----------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
---------------------------------------------------------------- -----------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
---------------------------------------------------------------- -----------------------------
An event changing the breakdown of voting rights
---------------------------------------------------------------- -----------------------------
Other (please X
specify):
Change to
notifiable
interest following
share issue
--------------------------------------------------------- ----- -----------------------------
3. Full name of person(s) OrbiMed Private Investments
subject to the VI, LP
notification obligation:
(iii)
----------------------------------------------------------- ----------------------------------
4. Full name of shareholder(s)
(if different from 3.):(iv)
----------------------------------------------------------- ----------------------------------
5. Date of the transaction May 19, 2017
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ----------------------------------
6. Date on which issuer May 23, 2017
notified:
----------------------------------------------------------- ----------------------------------
7. Threshold(s) that is/are Downward crossing of the 10%
crossed or threshold
reached: (vi, vii)
----------------------------------------------------------- ----------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- -------------------------------- ---------------------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
------------- --------------- --------------- -------------- -------------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ----------- ----------- -------------- ------------ ------------ ------------ -----------
GB00B06GSH43 4,669,847 4,669,847 4,669,847 4,669,847 0 4.47% 0
------------- --------------- --------------- -------------- ------------ ------------ ------------ -----------
US9250501064 5,333,328 5,333,328 5,333,328 5,333,328 0 5.10% 0
------------- --------------- --------------- -------------- ------------ ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ------------- ------------------------------- ---------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- ------------- ------------- ---------------- ---------------------------- -----------------------
Nominal Delta
--------------- ------------- ------------- ---------------- ---------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------------------------------- -------------------------------------------------------------------
10,003,175 9.57%
------------------------------------------------- -------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
---------------------------------------------------------------------------------
These securities are held of record by OrbiMed Private
Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI
LLC ("GP VI") is the sole general partner of OPI VI,
and OrbiMed Advisors LLC ("Advisors"), is the sole managing
member of GP VI. Samuel D. Isaly ("Isaly"), a natural
person, is the managing member of, and holder of a controlling
interest in, Advisors.
Proxy Voting:
---------------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------------ -------------
11. Number of voting rights proxy
holder will cease to hold:
------------------------------------------------------------------ -------------
12. Date on which proxy holder will
cease to hold voting rights:
------------------------------------------------------------------ -------------
13. Additional information:
------------------------------------------------------------------ -------------
14. Contact name: Douglas Coon
------------------------------------------------------------------ -------------
15. Contact telephone number: 212-739-6400
------------------------------------------------------------------ -------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGUQPAUPMGQA
(END) Dow Jones Newswires
May 25, 2017 12:27 ET (16:27 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
